ATE228564T1 - Zusammensetzung aus mehreren immunreaktiven hepatitis-c-virus-polypeptiden - Google Patents

Zusammensetzung aus mehreren immunreaktiven hepatitis-c-virus-polypeptiden

Info

Publication number
ATE228564T1
ATE228564T1 AT92919917T AT92919917T ATE228564T1 AT E228564 T1 ATE228564 T1 AT E228564T1 AT 92919917 T AT92919917 T AT 92919917T AT 92919917 T AT92919917 T AT 92919917T AT E228564 T1 ATE228564 T1 AT E228564T1
Authority
AT
Austria
Prior art keywords
hepatitis
composition
virus polypeptides
multiple immunoreactive
immunoreactive
Prior art date
Application number
AT92919917T
Other languages
English (en)
Inventor
Amy J Weiner
Michael Houghton
Original Assignee
Chiron Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25056174&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE228564(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Chiron Corp filed Critical Chiron Corp
Application granted granted Critical
Publication of ATE228564T1 publication Critical patent/ATE228564T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/82—Hepatitis associated antigens and antibodies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/82—Proteins from microorganisms
    • Y10S530/826—Viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AT92919917T 1991-09-13 1992-09-11 Zusammensetzung aus mehreren immunreaktiven hepatitis-c-virus-polypeptiden ATE228564T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US75957591A 1991-09-13 1991-09-13
PCT/US1992/007683 WO1993006126A1 (en) 1991-09-13 1992-09-11 Immunoreactive hepatitis c virus polypeptide compositions

Publications (1)

Publication Number Publication Date
ATE228564T1 true ATE228564T1 (de) 2002-12-15

Family

ID=25056174

Family Applications (1)

Application Number Title Priority Date Filing Date
AT92919917T ATE228564T1 (de) 1991-09-13 1992-09-11 Zusammensetzung aus mehreren immunreaktiven hepatitis-c-virus-polypeptiden

Country Status (16)

Country Link
US (6) US5756312A (de)
EP (1) EP0608261B1 (de)
JP (5) JPH06511149A (de)
AT (1) ATE228564T1 (de)
AU (1) AU679429B2 (de)
BG (1) BG62973B1 (de)
CA (1) CA2116764C (de)
DE (1) DE69232859T2 (de)
DK (1) DK0608261T3 (de)
ES (1) ES2182822T3 (de)
FI (1) FI112438B (de)
HU (1) HU227510B1 (de)
PL (2) PL171489B1 (de)
RO (1) RO116199B1 (de)
RU (2) RU2136311C1 (de)
WO (1) WO1993006126A1 (de)

Families Citing this family (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6596476B1 (en) * 1989-12-22 2003-07-22 Abbott Laboratories Hepatitis C assay
DK0608261T3 (da) * 1991-09-13 2003-03-17 Chiron Corp Sammensætninger med immunreaktivt hepatitis C virus polypeptid
US6297048B1 (en) * 1992-02-04 2001-10-02 Chiron Corporation Hepatitis therapeutics
US6709828B1 (en) 1992-03-06 2004-03-23 N.V. Innogenetics S.A. Process for the determination of peptides corresponding to immunologically important epitopes and their use in a process for determination of antibodies or biotinylated peptides corresponding to immunologically important epitopes, a process for preparing them and compositions containing them
US6667387B1 (en) 1996-09-30 2003-12-23 N.V. Innogenetics S.A. HCV core peptides
EP0671926B1 (de) * 1992-08-11 2002-11-13 President And Fellows Of Harvard College Immunmodulierende peptide
US6762024B2 (en) * 1993-04-27 2004-07-13 Innogenetics, S.A. Sequences of hepatitis C virus genotypes and their use as therapeutic and diagnostic agents
US7255997B1 (en) 1993-04-27 2007-08-14 N.V. Innogenetics S.A. Sequences of hepatitis C virus genotypes and their use as therapeutic and diagnostic agents
EP0697888B1 (de) * 1993-05-12 2003-09-17 Chiron Corporation Konserviertes Motiv der Hepatitis C Virus E2/NS1 Region
US5514539A (en) * 1993-06-29 1996-05-07 The United States Of America As Represented By The Department Of Health And Human Services Nucleotide and deduced amino acid sequences of the envelope 1 gene of 51 isolates of hepatitis C virus and the use of reagents derived from these sequences in diagnostic methods and vaccines
ES2197170T3 (es) 1993-11-04 2004-01-01 Innogenetics N.V. Epitopos de celulas t humanas inmunologicamente dominantes del virus de la hepatitis c.
WO1996003652A1 (de) 1994-07-25 1996-02-08 Boehringer Mannheim Gmbh Bestimmung von spezifischem immunglobulin unter verwendung multipler antigene
EP1845108A3 (de) * 1994-07-29 2007-10-24 Innogenetics N.V. Monoklonale Antikörper gegen gereinigte Hüllproteine des Hepatitis-C-Virus für diagnostische und therapeutische Zwecke
DE69526973T3 (de) * 1994-10-21 2010-01-07 Innogenetics N.V. Sequenzen von hepatitis-c-virus genotype 7, und deren verwendung als vorbeugende, therapeutische und diagnostische mittel
US6110465A (en) * 1995-06-07 2000-08-29 The United States Of America As Represented By The Department Of Health And Human Services Nucleotide and deduced amino acid sequences of hypervariable region 1 of the envelope 2 gene of isolates of hepatitis C virus and the use of reagents derived from these hypervariable sequences in diagnostic methods and vaccines
US7235394B1 (en) 1995-08-29 2007-06-26 Washington University Functional DNA clone for hepatitis C virus (HCV) and uses thereof
US6127116A (en) * 1995-08-29 2000-10-03 Washington University Functional DNA clone for hepatitis C virus (HCV) and uses thereof
US7045363B2 (en) * 1996-05-01 2006-05-16 Fujirebio Inc. Nucleic acid-bound polypeptide method of producing nucleic acid-bound polypeptide and immunoassay using the polypeptide
US6001613A (en) * 1996-05-24 1999-12-14 Board Of Regents Of University Of Nebraska Plasmid bearing a cDNA copy of the genome of bovine viral diarrhea virus, chimeric derivatives thereof, and method of producing an infectious bovine viral diarrhea virus using said plasmid
JP4021493B2 (ja) 1996-11-08 2007-12-12 ザ ガヴァメント オブ ザ ユナイテッド ステイツ オブ アメリカ、レプリゼンテッド バイ ザ セクレタリー、 デパートメント オブ ヘルス アンド ヒューマン サーヴィスィズ Ｃ型肝炎ウイルス様粒子の合成および精製
US6322965B1 (en) * 1997-02-10 2001-11-27 Advanced Life Science Institute, Inc. Chimera antigen peptide
US7338759B1 (en) 1997-03-04 2008-03-04 Washington University HCV variants
US7049428B1 (en) * 1998-03-04 2006-05-23 Washington University HCV variants
WO1999024466A2 (en) * 1997-11-06 1999-05-20 Innogenetics N.V. Multi-mer peptides derived from hepatitis c virus envelope proteins for diagnostic use and vaccination purposes
US7157435B2 (en) 1998-04-15 2007-01-02 The Regents Of The University Of California Methods for modulation of the effects of aging on the primate brain
US6815431B2 (en) 1998-04-15 2004-11-09 Regents Of The University Of California Methods for therapy of neurodegenerative disease of the brain
US6683058B1 (en) 1998-04-15 2004-01-27 Regents Of The University Of California Methods for therapy of neurodegenerative disease of the brain
US6451306B1 (en) 1998-04-15 2002-09-17 The Regents Of The University Of California Methods for therapy of neurodegenerative disease of the brain
US7052830B1 (en) * 1998-06-09 2006-05-30 Branch Andrea D Hepatitis C virus peptides and uses thereof
US7108855B2 (en) * 1998-06-24 2006-09-19 Innogenetics N.V. Purified hepatitis C virus envelope proteins for diagnostic and therapeutic use
US6548634B1 (en) * 1998-09-30 2003-04-15 Chiron Corporation Synthetic peptides having FGF receptor affinity
US20030180284A1 (en) * 1998-11-05 2003-09-25 Board Of Trustees Of Leland Stanford Junior University Prevention and treatment of HCV infection employing antibodies directed against conformational and linear epitopes
US7091324B2 (en) 1998-11-05 2006-08-15 Board Of Trustees Of Leland Stanford Junior University Prevention and treatment of HCV infection employing antibodies directed against conformational epitopes
US7935805B1 (en) * 1998-12-31 2011-05-03 Novartis Vaccines & Diagnostics, Inc Polynucleotides encoding antigenic HIV Type C polypeptides, polypeptides and uses thereof
AU2221600A (en) 1998-12-31 2000-07-31 Chiron Corporation Improved expression of hiv polypeptides and production of virus-like particles
EP1141314A2 (de) * 1998-12-31 2001-10-10 Chiron Corporation Für antigene polypeptide des hiv type c kodierende polynukleotide, entsprechende polypeptide und verwendungen davon
ATE384795T1 (de) * 1998-12-31 2008-02-15 Novartis Vaccines & Diagnostic Modifizierte hiv env polypeptide
US6740323B1 (en) 1999-11-24 2004-05-25 Chiron Corporation HBV/HCV virus-like particle
EP1535628B1 (de) * 1999-11-24 2013-07-31 Novartis Vaccines and Diagnostics, Inc. Hbv/hcv virus-ähnliche teilchen
IL153831A0 (en) * 2000-07-19 2003-07-31 Univ California Methods for therapy of neurodegenerative disease of the brain
US7022830B2 (en) 2000-08-17 2006-04-04 Tripep Ab Hepatitis C virus codon optimized non-structural NS3/4A fusion gene
US6680059B2 (en) 2000-08-29 2004-01-20 Tripep Ab Vaccines containing ribavirin and methods of use thereof
CN100400101C (zh) 2000-08-17 2008-07-09 特里帕普股份公司 包含病毒唑的疫苗及其使用方法
US6858590B2 (en) 2000-08-17 2005-02-22 Tripep Ab Vaccines containing ribavirin and methods of use thereof
AU2001292667A1 (en) 2000-09-13 2002-03-26 Hawaii Biotechnology Group, Inc. Immunogenic composition of hepatitis c and methods of use thereof
RU2195668C2 (ru) * 2001-02-12 2002-12-27 Мешандин Алексей Гаврилович Способ постановки реакции агглютинационного иммунологического анализа
AU2002322358B2 (en) * 2001-06-29 2009-06-18 Novartis Vaccines And Diagnostics, Inc. HCV E1E2 vaccine compositions
EP1409694A4 (de) * 2001-07-05 2006-02-08 Chiron Corp Antigene typ-b- und/oder typ-c-hiv-polypeptide codierende polynukleotide, polypeptide und deren verwendungen
AU2002320314A1 (en) 2001-07-05 2003-01-21 Chiron, Corporation Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof
CA2458995C (en) * 2001-08-31 2013-04-30 Chiron Corporation Polynucleotides encoding antigenic hiv type b polypeptides, polypeptides and uses thereof
US20030170614A1 (en) * 2001-08-31 2003-09-11 Megede Jan Zur Polynucleotides encoding antigenic HIV type B polypeptides, polypeptides and uses thereof
AR045702A1 (es) * 2001-10-03 2005-11-09 Chiron Corp Composiciones de adyuvantes.
NZ540194A (en) * 2002-11-08 2008-07-31 Ablynx Nv Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor
EP1628680B1 (de) 2003-05-15 2012-10-24 Novartis Vaccines and Diagnostics, Inc. Hiv polynucleotide und polypeptide von botswana mj4
US20050202036A1 (en) * 2003-07-22 2005-09-15 Branch Andrea D. Alternate reading frame polypeptides drived from hepatitis C and methods of their use
US20050130131A1 (en) * 2003-08-14 2005-06-16 California Institute Of Molecular Medicine Method for isolation and replication of infectious human hepatitis-C virus
US8124747B2 (en) 2003-08-29 2012-02-28 Innogenetics HCV clade and prototype sequences thereof
WO2006050394A2 (en) 2004-11-01 2006-05-11 Novartis Vaccines And Diagnostics Inc. Combination approaches for generating immune responses
EP1888751A2 (de) * 2005-05-25 2008-02-20 Tripep Ab Nichtstrukturelles ns3/4a-fusionsgen des hepatitis-c-virus
GB0524066D0 (en) * 2005-11-25 2006-01-04 Chiron Srl 741 ii
CA2637600A1 (en) 2006-01-17 2007-07-26 Health Research, Inc. Heteroduplex tracking assay
WO2009022236A2 (en) 2007-08-16 2009-02-19 Tripep Ab Immunogen platform
EP2201023A2 (de) * 2007-09-14 2010-06-30 GENimmune N.V. Affinitäts-tag
KR102069498B1 (ko) 2007-09-28 2020-01-23 포톨라 파마슈티컬스, 인코포레이티드 인자 Ｘａ 저해제에 대한 안티도트 및 그것을 사용하는 방법
WO2009130588A2 (en) * 2008-04-22 2009-10-29 Tripep Ab Immunogen platform
US20100104555A1 (en) * 2008-10-24 2010-04-29 The Scripps Research Institute HCV neutralizing epitopes
PL3604510T3 (pl) 2009-03-30 2025-07-28 Alexion Pharmaceuticals, Inc. Antidota na inhibitory czynnika xa i sposoby ich stosowania
US20100322943A1 (en) 2009-06-17 2010-12-23 Thomas Cantor Therapeutic and diagnostic affinity purified specific polyclonal antibodies
EP2453910B1 (de) 2009-07-15 2016-08-31 Portola Pharmaceuticals, Inc. Einzeldosisformulierung von antidoten für faktor-xa-hemmer zur prävention von blutung
US9655845B2 (en) 2011-07-06 2017-05-23 Glaxosmithkline Biologicals, S.A. Oil-in-water emulsions that contain nucleic acids
US9636410B2 (en) 2011-07-06 2017-05-02 Glaxosmithkline Biologicals Sa Cationic oil-in-water emulsions
US8609355B2 (en) 2011-07-26 2013-12-17 Indicator Systems International, Inc. Assays for the detection of microbes
FR2984328B1 (fr) 2011-12-20 2016-12-30 Bio-Rad Innovations Procede de detection d'une infection par le virus de l'hepatite c
AU2013234046B2 (en) 2012-03-16 2017-09-07 University Health Network Methods and compositions for modulating Toso activity
RU2520710C1 (ru) * 2012-12-10 2014-06-27 Государственное бюджетное образовательное учреждение высшего профессионального образования "Челябинская государственная медицинская академия" Министерства здравоохранения и социального развития Российской Федерации (ГБОУ ВПО ЧелГМА Минздравсоцразвития России) Способ прогнозирования персистенции онкогенных типов вируса папилломы человека в цервикальном эпителии
WO2015132672A2 (en) 2014-03-07 2015-09-11 University Health Network Methods and compositions for detection of targets involved in cancer metastasis
RU2675108C2 (ru) * 2015-06-15 2018-12-17 Федеральное государственное бюджетное научное учреждение "Научно-исследовательский институт биомедицинской химии имени В.Н. Ореховича" (ИБМХ) Композиция на основе синтетических пептидов и липидов для вакцины против гепатита с
US10287338B2 (en) 2015-07-10 2019-05-14 Miran NERSISSIAN Factor VIII protein compositions and methods of treating of hemophilia A
EP3365027B1 (de) 2015-10-14 2022-03-30 Research Institute at Nationwide Children's Hospital Hu-spezifische antikörper und deren verwendeng zur hemmung von biofilm
AU2018206560B9 (en) 2017-01-04 2025-04-03 Research Institute At Nationwide Children's Hospital Antibody fragments for the treatment of biofilm-related disorders
EP3565589A1 (de) 2017-01-04 2019-11-13 Research Institute at Nationwide Children's Hospital Dnabii-impfstoffe und antikörper mit erhöhter aktivität
EP3595445B1 (de) 2017-03-15 2024-09-04 The Research Institute at Nationwide Children's Hospital Zusammensetzung und verfahren zur brechung bakterieller biofilme ohne begleitentzündung
US20210139610A1 (en) 2018-06-29 2021-05-13 Research Institute At Nationwide Children's Hospital Compositions and methods for mediating eps
CA3145385A1 (en) 2019-07-08 2021-01-14 Steven D. Goodman Antibody compositions for disrupting biofilms

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3400079A1 (de) * 1984-01-03 1985-07-11 Röhm GmbH, 6100 Darmstadt Wasserspreitendes kunststoffmaterial, verfahren zu seiner herstellung u. verwendung als verglasungs- und bedachungsmaterial
US4673634A (en) * 1985-03-08 1987-06-16 The United States Of America As Represented By The Department Of Health And Human Services Purified antigen from non-A, non-B hepatitis causing factor
JPS6391328A (ja) * 1986-10-07 1988-04-22 Mitsubishi Kasei Corp 非ａ非ｂ型肝炎抗原
NZ219516A (en) * 1987-02-10 1991-02-26 Wellcome Found Fusion proteins of hbcag (hepatitis b virus core antigen)
WO1989004669A1 (en) * 1987-11-18 1989-06-01 Chiron Corporation Nanbv diagnostics and vaccines
US5350671A (en) * 1987-11-18 1994-09-27 Chiron Corporation HCV immunoassays employing C domain antigens
US5191064A (en) * 1988-09-30 1993-03-02 The Research Foundation For Microbial Diseases (Osaka University) Non-a, non-b hepatitis virus antigen peptide
JPH02167081A (ja) * 1988-12-21 1990-06-27 Tetsuo Nakamura 非Ａ非Ｂ型肝炎ウイルスゲノムＲＮＡ、ｃＤＮＡおよびウイルス抗原蛋白質
HUT54896A (en) * 1989-03-17 1991-04-29 Chiron Corp Process for producing aquous diagnosticum and vaccine of nanbv
WO1990014436A1 (en) * 1989-05-18 1990-11-29 Chiron Corporation Nanbv diagnostics: polynucleotides useful for screening for hepatitis c virus
US5372928A (en) * 1989-09-15 1994-12-13 Chiron Corporation Hepatitis C virus isolates
WO1991004262A1 (en) * 1989-09-15 1991-04-04 National Institute Of Health Of Japan New hcv isolates
DK0770679T4 (da) * 1990-11-03 2010-05-10 Siemens Healthcare Diagnostics HCV-specifikke peptider, sammensætninger dertil og anvendelse deraf
DK0608261T3 (da) * 1991-09-13 2003-03-17 Chiron Corp Sammensætninger med immunreaktivt hepatitis C virus polypeptid

Also Published As

Publication number Publication date
JP2005176853A (ja) 2005-07-07
CA2116764C (en) 1999-12-07
HU9400741D0 (en) 1994-06-28
US5766845A (en) 1998-06-16
US5670153A (en) 1997-09-23
FI941199L (fi) 1994-04-27
EP0608261A1 (de) 1994-08-03
PL171489B1 (pl) 1997-05-30
US6303292B1 (en) 2001-10-16
AU679429B2 (en) 1997-07-03
RU2212899C2 (ru) 2003-09-27
AU2643692A (en) 1993-04-27
DE69232859D1 (de) 2003-01-16
DE69232859T2 (de) 2003-04-10
HU227510B1 (en) 2011-07-28
WO1993006126A1 (en) 1993-04-01
US5756312A (en) 1998-05-26
ES2182822T3 (es) 2003-03-16
BG98653A (bg) 1995-05-31
FI112438B (fi) 2003-12-15
HUT67342A (en) 1995-03-28
CA2116764A1 (en) 1993-04-01
JP2002167336A (ja) 2002-06-11
EP0608261A4 (de) 1995-03-15
US5670152A (en) 1997-09-23
JP2008133301A (ja) 2008-06-12
RU2136311C1 (ru) 1999-09-10
JP4353905B2 (ja) 2009-10-28
EP0608261B1 (de) 2002-11-27
RO116199B1 (ro) 2000-11-30
JPH06511149A (ja) 1994-12-15
US5728520A (en) 1998-03-17
DK0608261T3 (da) 2003-03-17
JP2004073207A (ja) 2004-03-11
BG62973B1 (bg) 2000-12-29
PL171972B1 (pl) 1997-07-31
FI941199A0 (fi) 1994-03-14

Similar Documents

Publication Publication Date Title
DE69232859D1 (de) Zusammensetzung aus mehreren immunreaktiven hepatitis-c-virus-polypeptiden
FI935808A0 (fi) Hepatit-C-virus (HCV) polypeptider
RU94024561A (ru) Иммунореактивные композиции, способ получения композиции, способы получения и обнаружения антител, набор днк, клетка-хозяин, способ получения белка
EE200100292A (et) Peptiidligandidega kinnituvate mitmeste immunogeensete komponentidega HBV tuuma antigeensed osakesed
FI932561A0 (fi) Proteiner med foeraendrade epitoper och foerfaranden foer deras framstaellning
ATA117890A (de) Komplexes virales antigen von hiv-1 bindendes rekombinantes protein
ATE496630T1 (de) Immunologische zusammensetzung und impfstoffe, die einen auf n-formyl-methionyl peptide bestehenden adjuvans enthalten
DE69433971D1 (de) Von menschlichen T-Zellen immunodominante Epitopen des Virus der C-Hepatitis
ATA257190A (de) Virales polypeptid
CA2103887A1 (en) Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof
DK643387A (da) T-celle-epitoper af hepatitis b-virus-nucleocapsid-protein
ATE173275T1 (de) Von einem retrovirus aus der hiv-gruppe abgeleitete peptide und deren verwendung
IL101425A0 (en) Peptides and mixtures thereof for detecting antibodies to hepatitis c virus,methods for their use and pharmaceutical compositions containing the same
DK0754704T3 (da) Syntetiske antigener til påvisning af antistoffer mod hepatitis c-virus
IL128826A0 (en) A crystallizable composition comprising a hepatitis C virus NS3 like polypeptide complexed with a NS4 a-like peptide
ATE231557T1 (de) Detektion des hepatis-c virus.
ES8500997A1 (es) Un metodo para producir un peptido.
IT8347560A0 (it) Polipeptide dotato di attivita' di interferon, composizione che lo con tiene e procedimento di preparazione
ATE308618T1 (de) Mimotopen der hypervariabele region des e2 glykoproteins von hcv und deren verwendungen
FR2676068B1 (fr) Souches recombinantes immunogenes de b. anthracis - compositions immunogenes les contenant.
AU2370592A (en) Epitopes of the env protein of the hepatitis c virus
DE3751834D1 (de) Selbstantigen der primären lebercirrhose
DE69132200D1 (de) Immunaktive Peptidzusammensetzung gegen HTLV-Antikörper
IT1164861B (it) Polipeptide avente attivita' di interferon, composizione che lo contiene e procedimento di preparazione
DK196689D0 (da) Ekspression af praes2-proteinet for hepatitis b i methylotrophe gaerarter

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0608261

Country of ref document: EP